Edoras Investment Holdings discloses substantial acquisition in Nephrocare Health Services Limited under SEBI Takeover Code
Edoras Investment Holdings Pte. Ltd, a Singapore-incorporated investment entity, submitted disclosure documentation to NSE on 8 May 2026 under Regulation 31(4) of the SEBI (SAST) Regulations, 2011. This disclosure typically follows either (i) acquisition crossing 25% threshold, or (ii) acquisition of control. Nephrocare Health Services Limited operates in the specialised renal care segment in India. The filing triggers mandatory open-offer obligations; the acquirer must now publish an open offer to acquire up to 26% of public shareholding at a price determined per Schedule IV methodology.
Why it mattersThe 31(4) disclosure signals a trigger event (likely crossing 25% threshold or acquisition of controlling interest); counsel must immediately verify trigger threshold, compute open-offer price band, and confirm exemptions under Regulation 10 or 12 if applicable.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Corporate Archives (NSE EMERGE Portal) · official
- NSE Listing Compliance · official
- Nephrocare Health Services Limited – Investor Relations · official
- SEBI SAST Regulations, 2011 (as amended) · official
- RBI Master Circular on FDI (2024 as amended) · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026